



# How is REXULTI<sup>®</sup> (brexpiprazole) thought to work?

5-HT, serotonin; D, dopamine; NE, norepinephrine.

## **INDICATION and IMPORTANT SAFETY INFORMATION for REXULTI<sup>®</sup> (brexpiprazole)**

### **INDICATION**

REXULTI is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.

### **IMPORTANT SAFETY INFORMATION**

#### **WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS**

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.

#### **WARNING: SUICIDAL THOUGHTS AND BEHAVIORS**


Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients and young adult patients. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. The safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.

Please see [IMPORTANT SAFETY INFORMATION](#) on pages 4 and 5, including **BOXED WARNING**.

## REXULTI® (brexpiprazole) targets 3 neurotransmitter systems

The only atypical antipsychotic indicated as an adjunctive therapy to antidepressants for the treatment of MDD with high binding affinity to norepinephrine, serotonin, and dopamine receptors<sup>1-4</sup>

### ANTIDEPRESSANT + REXULTI



Many antidepressants, such as SSRIs, are reuptake inhibitors and are thought to work by blocking the presynaptic reabsorption of serotonin. SNRIs and NDRI function in similar ways for other neurotransmitter transporters.

REXULTI is thought to work differently by acting as an antagonist and partial agonist on norepinephrine, serotonin, and dopamine receptors.


The mechanism of action of REXULTI is unknown. The activity of these compounds is based on *in vitro* data. The clinical significance of the *in vitro* data is unknown. Reuptake inhibitors modulate neurotransmitter activity through different processes than partial agonists and antagonists.<sup>5</sup> The pharmacology data of REXULTI do not provide further insights on the mechanism of action.

5-HT, serotonin; D, dopamine; MDD, major depressive disorder; NDRI, norepinephrine and dopamine reuptake inhibitor; NE, norepinephrine; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.



## REXULTI® (brexpiprazole) has high binding affinity to 3 neurotransmitter systems: norepinephrine, serotonin, and dopamine<sup>6</sup>

Pharmacodynamic profile—binding affinities across neurotransmitter systems<sup>7,a</sup>



## Norepinephrine, serotonin, and dopamine modulate each other's activity.<sup>8</sup>

While the mechanism of action of REXULTI is unknown, the efficacy of REXULTI may be mediated through a combination of partial agonist activity at serotonin  $5-HT_{1A}$  and dopamine  $D_2$  receptors, and antagonist activity at serotonin  $5-HT_{2A}$  receptors. The activity of these compounds is based on *in vitro* data. The clinical significance of the *in vitro* data is unknown.



**4-hour peak plasma concentration** (after administration)




**Half-life**

<sup>a</sup>The binding affinity of brexpiprazole was determined *in vitro* in cells overexpressing human receptors and is expressed as an nM concentration with lower values representing higher affinity. High binding affinity  $K_i < 1$  nM.

5-HT, serotonin; D, dopamine;  $K_i$ , binding affinity; NDRI, norepinephrine and dopamine reuptake inhibitor; NE, norepinephrine; nM, nanomolar; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

Watch a video featuring  
Dr. Rakesh Jain to  
learn more



SCAN TO WATCH VIDEO

Rakesh Jain, MD, MPH

## INDICATION and IMPORTANT SAFETY INFORMATION for REXULTI® (brexpiprazole)

### INDICATION

REXULTI is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.

### IMPORTANT SAFETY INFORMATION

#### WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.

#### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients and young adult patients. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. The safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.

**Contraindication:** In patients with known hypersensitivity to brexpiprazole or any of its components. Reactions have included: rash, facial swelling, urticaria, and anaphylaxis.

**Cerebrovascular Adverse Events, Including Stroke:** In clinical trials, elderly patients with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.

**Neuroleptic Malignant Syndrome (NMS):** NMS is a potentially fatal symptom complex reported in association with administration of antipsychotic drugs, including REXULTI. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of REXULTI, intensive symptomatic treatment, and monitoring.

**Tardive Dyskinesia (TD):** Risk of TD, and the potential to become irreversible, appear to increase with duration of treatment and total cumulative dose of antipsychotic drugs. TD can develop after relatively brief treatment periods, at low doses, or after discontinuation of treatment. For chronic treatment, use the lowest dose and shortest duration of REXULTI needed to produce a clinical response. If signs and symptoms of TD appear, drug discontinuation should be considered.

## INDICATION and IMPORTANT SAFETY INFORMATION for REXULTI® (brexpiprazole) (cont'd)

**Metabolic Changes:** Atypical antipsychotic drugs, including REXULTI, have caused metabolic changes including:

- **Hyperglycemia/Diabetes Mellitus:** Hyperglycemia and diabetes mellitus, in some cases extreme and associated with diabetic ketoacidosis, hyperosmolar coma, or death, have been reported in patients treated with atypical antipsychotics. Assess fasting plasma glucose before or soon after initiation of antipsychotic medication and monitor periodically during long-term treatment.
- **Dyslipidemia:** Atypical antipsychotics cause adverse alterations in lipids. Before or soon after initiation of antipsychotic medication, obtain a fasting lipid profile at baseline and monitor periodically during treatment.
- **Weight Gain:** Weight gain has been observed in patients treated with REXULTI. Monitor weight at baseline and frequently thereafter.

**Pathological Gambling and Other Compulsive Behaviors:** Intense urges, particularly for gambling, and the inability to control these urges have been reported while taking REXULTI. Other compulsive urges have been reported less frequently. Prescribers should ask patients or their caregivers about the development of new or intense compulsive urges. Consider dose reduction or stopping REXULTI if such urges develop.

**Leukopenia, Neutropenia, and Agranulocytosis:** Leukopenia and neutropenia have been reported with antipsychotics. Agranulocytosis (including fatal cases) has been reported with other agents in this class. Monitor complete blood count in patients with pre-existing low white blood cell count (WBC)/absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue REXULTI at the first sign of a clinically significant decline in WBC and in patients with severe neutropenia.

**Orthostatic Hypotension and Syncope:** Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest during initial dose titration and when increasing the dose. Monitor in patients vulnerable to hypotension and those with cardiovascular and cerebrovascular diseases.

**Falls:** Antipsychotics may cause somnolence, postural hypotension, and motor and sensory instability, which may lead to falls causing fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during treatment.

**Seizures:** REXULTI may cause seizures and should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

**Body Temperature Dysregulation:** Use REXULTI with caution in patients who may experience conditions that increase body temperature (eg, strenuous exercise, extreme heat, dehydration, or concomitant use with anticholinergics).

**Dysphagia:** Esophageal dysmotility and aspiration have been associated with antipsychotics, including REXULTI, and should be used with caution in patients at risk for aspiration.

**Potential for Cognitive and Motor Impairment:** REXULTI may cause somnolence and has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including operating motor vehicles, until they are reasonably certain REXULTI does not affect them adversely.

**Concomitant Medication:** Dosage adjustments are recommended in patients who are known cytochrome P450 (CYP) 2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers.

**Most commonly observed adverse reactions:** In clinical trials of adults, the most common adverse reactions were:

- **Major Depressive Disorder (MDD)** (adjunctive treatment to antidepressant therapy;  $\geq 5\%$  incidence and at least twice the rate of placebo for REXULTI vs placebo): weight increased, somnolence, and akathisia.

**Dystonia:** Symptoms of dystonia may occur in susceptible individuals during the first days of treatment and at low doses.

**Pregnancy:** Adequate and well-controlled studies to assess the risks of REXULTI during pregnancy have not been conducted. REXULTI should be used during pregnancy only if the benefit justifies the risk to the fetus.

**Lactation:** It is not known if REXULTI is excreted in human breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 ([www.fda.gov/medwatch](http://www.fda.gov/medwatch)).

Please see [FULL PRESCRIBING INFORMATION](#), including **BOXED WARNING**.

**References:** **1.** Seroquel XR. Prescribing information. AstraZeneca Pharmaceuticals LP; 2022. **2.** Abilify. Prescribing information. Otsuka Pharmaceutical Company; 2022. **3.** Latuda. Prescribing information. Sunovion Pharmaceuticals Inc; 2022. **4.** Vraylar. Prescribing information. Allergan Pharmaceuticals International Limited; 2024. **5.** Ross EM, Kenakin TP. Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect. In: Hardman JG, Limbird LE, eds. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 10th ed. New York, NY: McGraw-Hill; 2001:31-43. **6.** Stahl SM. *Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications*. 4th ed. Cambridge University Press; 2013. **7.** Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. *J Pharmacol Exp Ther*. 2014;350(3):589-604. **8.** Mansari M, Guiard BP, Chernoloz O, et al. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. *CNS Neurosci Ther*. 2010;16(3):e1-e17. doi:10.1111/j.1755-5949.2010.00146.x



© 2025 Otsuka America Pharmaceutical, Inc. All rights reserved.  
September 2025 11US25EBP0282